MS decreases the larger amplitude distribution in adult rats. by Jesús David Ayala-Rodríguez (17364296)

N-acetilcysteine prevents the <i>A</i>. <i>simplex</i> CE-induced TEER decrease. by Noelia Carballeda-Sangiao (2889611)

Word clouds form N = 4 LDA topic modeling with greater words signaling greater significance. by Philipp Wicke (9443631)

A noxious temperature decrease without a prior increase produces a subtly larger decrease in pain intensity. by Benedict J. Alter (9745466)

Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15. by Therese M. Gilligan (7460906)

JNJ26993135 + BML-111 decreases permeability and enhances ZO-1 and claudin-1 induced by PAF but does not change TEER. by Kameljit K. Kalsi (16496511)

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Transepithelial electrical resistance (TEER) (N = 6). by Shirko Marcel Shokr (19173337)

“…<p><b>(A)</b> During the cultivation of SMC and ALI we observed significantly differences on day 18 (SMC: 9.61 kΩ*cm²; ALI: 7.73 kΩ*cm²; p<0.05) and day 25 (SMC: 8.19 kΩ*cm²; ALI: 6.44 kΩ*cm²; p<0.05) ALI cultures showed significantly decreased values compared to SMC. …”

GO categories for which Z is significantly greater than 1, for each of the population comparisons. by Vivak Soni (12732884)

VZV exposed or infected MAIT cells do not exhibit significantly greater levels of apoptosis. by Shivam. K. Purohit (19346538)

Geographic distribution of ZCTA-level COVID-19 risk and its significant predicators in the Greater St. Louis area, Missouri (USA). by Praachi Das (13876574)

Final global negative binomial model showing significant predictors of COVID-19 risk in the Greater St. Louis Area, Missouri (USA). by Praachi Das (13876574)

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Patients with high baseline gut richness and diversity have significantly greater decreases in diversity over time. by Molly B. El Alam (10231830)

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects: